Skip to main content
Erschienen in: Pathology & Oncology Research 2/2019

08.01.2019 | Original Article

Relationship Between -2028 C/T SELP Gene Polymorphism, Concentration of Plasma P-Selectin and Risk of Malnutrition in Head and Neck Cancer Patients

verfasst von: Tomasz Powrózek, Radosław Mlak, Anna Brzozowska, Marcin Mazurek, Paweł Gołębiowski, Teresa Małecka-Massalska

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Until today there is a lack of molecular factors, that could predict either cancer malnutrition or cachexia. Among potential mechanisms, that contribute to development of above syndromes, the systemic inflammatory response with overproduction of cytokines and adhesion molecules is the most likely. Recent papers suggested crucial role of P-selectin adhesion molecule in the initiation of leukocytes recruitment to the site of injury during inflammation, promotion of tumor aggressiveness and contribution to cancer cachexia. The aim of the study was to investigate SELP -2028 C/T polymorphism as a risk factor of malnutrition in 66 head and neck cancer (HNC) patients subjected to radiotherapy. Genotyping was conducted by real-time PCR method by means of TaqMan SNP Genotyping Assay. P-selectin Human ELISA Kit was used to determine P-selectin concentration in each extracted plasma samples. CC homozygous subjects had 4-fold higher risk score of being qualified as severely malnourished compared to other genotype carriers (p = 0.015). However, the TT homozygous patients were at lowest risk of severe weight loss >10% during the therapy period (OR = 0.20; p = 0.019). We also noted, that CC genotype carriers had significantly higher risk of early death incidence compared to CT or TT genotype (median survival time: 29 vs 34 months; HR = 3.02; p = 0.0085). Studied SELP -2028 C/T seems to be a novel attractive predictive factor of cancer malnutrition in HNC patients, perhaps in a future, patients carrying unfavorable CC genotype could be earlier scheduled for pharmaceutical intervention with parenterall nutrition, therefore they could be prevented from the development of severe malnutrition or even cachexia.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat O’Neill J, Shaha A (2011) Nutrition management of patients with malignancies of the head and neck. Surg Clin North Am 91:631–639CrossRefPubMed O’Neill J, Shaha A (2011) Nutrition management of patients with malignancies of the head and neck. Surg Clin North Am 91:631–639CrossRefPubMed
2.
Zurück zum Zitat Alshadwi A, Nadershah M, Carlson ER, Young LS, Burke PA, Daley BJ (2013) Nutritional considerations for head and neck cancer patients: a review of the literature. J Oral Maxillofac Surg 71(11):1853–1860CrossRefPubMed Alshadwi A, Nadershah M, Carlson ER, Young LS, Burke PA, Daley BJ (2013) Nutritional considerations for head and neck cancer patients: a review of the literature. J Oral Maxillofac Surg 71(11):1853–1860CrossRefPubMed
3.
Zurück zum Zitat Unsal D, Mentes B, Akmansu M, Uner A, Oguz M, Pak Y (2006) Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study. Am J Clin Oncol 29:183–188CrossRefPubMed Unsal D, Mentes B, Akmansu M, Uner A, Oguz M, Pak Y (2006) Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study. Am J Clin Oncol 29:183–188CrossRefPubMed
4.
Zurück zum Zitat Gorenc M, Kozjek NR, Strojana P (2015) Malnutrition and cachexia in patients with head and neck cancer treated with (chemo)radiotherapy. Rep Pract Oncol Radiother 20(4):249–258CrossRefPubMedPubMedCentral Gorenc M, Kozjek NR, Strojana P (2015) Malnutrition and cachexia in patients with head and neck cancer treated with (chemo)radiotherapy. Rep Pract Oncol Radiother 20(4):249–258CrossRefPubMedPubMedCentral
6.
7.
Zurück zum Zitat Donohoe CL, Ryan AM, Reynolds JV (2011, 601434) Cancer Cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011:1–13CrossRef Donohoe CL, Ryan AM, Reynolds JV (2011, 601434) Cancer Cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011:1–13CrossRef
9.
Zurück zum Zitat Geng JG, Chen M, Chou KC (2004) P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem 11(16):2153–2160CrossRefPubMed Geng JG, Chen M, Chou KC (2004) P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem 11(16):2153–2160CrossRefPubMed
10.
Zurück zum Zitat Reiner AP, Carlson CS, Thyagarajan B, Rieder MJ, Polak JF, Siscovick DS, Nickerson DA, Jacobs DR Jr, Gross MD (2008) Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the coronary artery risk development in young adults (CARDIA) study. Send to Arterioscler Thromb Vasc Biol 28(8):1549–1555CrossRef Reiner AP, Carlson CS, Thyagarajan B, Rieder MJ, Polak JF, Siscovick DS, Nickerson DA, Jacobs DR Jr, Gross MD (2008) Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the coronary artery risk development in young adults (CARDIA) study. Send to Arterioscler Thromb Vasc Biol 28(8):1549–1555CrossRef
11.
Zurück zum Zitat Burkhardt J, Blume M, Petit-Teixeira E, Hugo Teixeira V, Steiner A, Quente E, Wolfram G, Scholz M, Pierlot C, Migliorini P, Bombardieri S, Balsa A, Westhovens R, Barrera P, Radstake TRDJ, Alves H, Bardin T, Prum B, Emmrich F, Cornelis F, Ahnert P, Kirsten H (2014) Cellular adhesion gene SELP is associated with rheumatoid arthritis and displays differential allelic expression. PLoS One 9(8):e103872CrossRefPubMedPubMedCentral Burkhardt J, Blume M, Petit-Teixeira E, Hugo Teixeira V, Steiner A, Quente E, Wolfram G, Scholz M, Pierlot C, Migliorini P, Bombardieri S, Balsa A, Westhovens R, Barrera P, Radstake TRDJ, Alves H, Bardin T, Prum B, Emmrich F, Cornelis F, Ahnert P, Kirsten H (2014) Cellular adhesion gene SELP is associated with rheumatoid arthritis and displays differential allelic expression. PLoS One 9(8):e103872CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Fearon KC, Glass DJ, Guttridge DC (2012) Cancer Cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166CrossRefPubMed Fearon KC, Glass DJ, Guttridge DC (2012) Cancer Cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166CrossRefPubMed
13.
Zurück zum Zitat Avan A, Avan A, Le Large TY et al (2014) AKT1 and SELP polymorphisms predict the risk of developing Cachexia in pancreatic Cancer patients. PLoS ONE 9(9):e108057CrossRefPubMedPubMedCentral Avan A, Avan A, Le Large TY et al (2014) AKT1 and SELP polymorphisms predict the risk of developing Cachexia in pancreatic Cancer patients. PLoS ONE 9(9):e108057CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kaur R, Singh J, Kaur M (2017) Structural and functional impact of SNPs in P-selectin gene: a comprehensive in silico analysis. Open Life Sciences 12(1):19–33CrossRef Kaur R, Singh J, Kaur M (2017) Structural and functional impact of SNPs in P-selectin gene: a comprehensive in silico analysis. Open Life Sciences 12(1):19–33CrossRef
15.
Zurück zum Zitat Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Boerwinkle E (2007) Specific P-selectin and P-selectin glycoprotein ligand–1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 195:e76–e82CrossRefPubMedPubMedCentral Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Boerwinkle E (2007) Specific P-selectin and P-selectin glycoprotein ligand–1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 195:e76–e82CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jacobin VM, Deramchia K, Mornet S et al (2011) MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed 24:413–424 Jacobin VM, Deramchia K, Mornet S et al (2011) MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed 24:413–424
17.
Zurück zum Zitat Miller MA, Kerry SM, Dong Y, Strazzullo P, Cappuccio FP (2004) Association between the Thr715Pro Pselectin gene polymorphism and soluble P-selectin levels in a multiethnic population in South London. Thromb Haemost 92:1060–1065CrossRefPubMed Miller MA, Kerry SM, Dong Y, Strazzullo P, Cappuccio FP (2004) Association between the Thr715Pro Pselectin gene polymorphism and soluble P-selectin levels in a multiethnic population in South London. Thromb Haemost 92:1060–1065CrossRefPubMed
18.
Zurück zum Zitat Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Wu KK, Boerwinkle E (2006) P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the atherosclerosis risk in communities study. Atherosclerosis 186:74–79CrossRefPubMed Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Wu KK, Boerwinkle E (2006) P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the atherosclerosis risk in communities study. Atherosclerosis 186:74–79CrossRefPubMed
19.
Zurück zum Zitat Kou L, Yang N, Chen G et al (2016) Association of SELP genetic polymorphisms and additional gene-smoking interaction on cardiovascular disease in Chinese Han population. Int J Clin Exp Pathol 9(9):9612–9618 Kou L, Yang N, Chen G et al (2016) Association of SELP genetic polymorphisms and additional gene-smoking interaction on cardiovascular disease in Chinese Han population. Int J Clin Exp Pathol 9(9):9612–9618
20.
Zurück zum Zitat Morris DL, Graham RR, Erwig LP, Gaffney PM, Moser KL, Behrens TW, Vyse TJ, Graham DSC (2009) Variation in the upstream region of P-selectin (SELP) is a risk factor for SLE. Genes Immun 10:404–413CrossRefPubMedPubMedCentral Morris DL, Graham RR, Erwig LP, Gaffney PM, Moser KL, Behrens TW, Vyse TJ, Graham DSC (2009) Variation in the upstream region of P-selectin (SELP) is a risk factor for SLE. Genes Immun 10:404–413CrossRefPubMedPubMedCentral
21.
22.
Zurück zum Zitat Johns N, Stretch C, Tan BHL (2017) New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle 8(1):122–130CrossRefPubMed Johns N, Stretch C, Tan BHL (2017) New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle 8(1):122–130CrossRefPubMed
Metadaten
Titel
Relationship Between -2028 C/T SELP Gene Polymorphism, Concentration of Plasma P-Selectin and Risk of Malnutrition in Head and Neck Cancer Patients
verfasst von
Tomasz Powrózek
Radosław Mlak
Anna Brzozowska
Marcin Mazurek
Paweł Gołębiowski
Teresa Małecka-Massalska
Publikationsdatum
08.01.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-00578-w

Weitere Artikel der Ausgabe 2/2019

Pathology & Oncology Research 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.